La Crosse Virus Nucleocapsid (LACV N) (AA 90-140) anticorps
L’anticorps anti-La Crosse Virus Nucleocapsid Polyclonal Lapin est utilisé pour la détection de La Crosse Virus Nucleocapsid dans des échantillons de La Crosse Virus (LACV). Il a été validé pour ELISA.
Aperçu rapide pour La Crosse Virus Nucleocapsid (LACV N) (AA 90-140) anticorps (ABIN6991880)
Antigène
La Crosse Virus Nucleocapsid (LACV N)
Reactivité
La Crosse Virus (LACV)
Hôte
Lapin
Clonalité
Polyclonal
Conjugué
Inconjugué
Application
ELISA
Épitope
AA 90-140
Purification
La Crosse Virus Nucleocapsid Antibody is affinity chromatography purified via peptide column.
Immunogène
La Crosse virus nucleocapsid antibody was raised against an 18 amino acid peptide near the center of the La Crosse virus nucleocapsid. The immunogen is located within amino acids 90 - 140 of La Crosse Virus Nucleocapsid.
LACV N
Reactivité: Virus
ELISA
Hôte: Lapin
Polyclonal
unconjugated
Indications d'application
La Crosse virus nucleocapsid antibody can detect 10 ng La Crosse virus nucleocapsid peptide in ELISA at 1 μ,g/mL.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
La Crosse virus nucleocapsid Antibody is supplied in PBS containing 0.02 % sodium azide.
Agent conservateur
Sodium azide
Précaution d'utilisation
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Stock
-20 °C,4 °C
Stockage commentaire
Rift Valley Fever Virus Nucleocapsid antibody can be stored at 4°C for three months and -20°C, stable for up to one year.
Antigène
La Crosse Virus Nucleocapsid (LACV N)
Autre désignation
La Crosse Virus Nucleocapsid
Classe de substances
Viral Protein
Sujet
La Crosse Virus Nucleocapsid Antibody: La Crosse virus (LCV) is a single-stranded RNA virus that can cause encephalitis in humans and is transmitted predominantly by mosquitoes. It is often mistaken for herpes simplex encephalitis (1). During human infections, LCV initially presents as a nonspecific summertime illness with fever, headache, nausea, vomiting and lethargy. Death occurs in less than 1 % of clinical cases.